BioCentury | May 12, 2014
Emerging Company Profile

Inotrem: Sepsis companion

Inotrem S.A. is betting that a companion diagnostic can help its TREM1 inhibitors tamp down inflammation in the right sepsis patients and improve its odds of success in an indication where the only approved drug...
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BioCentury | Mar 15, 2010
Company News

BioXell, Cosmo deal

Cosmo completed its previously announced acquisition of BioXell (see BioCentury, Nov. 23, 2009). BioXell S.p.A. (SIX:BXLN), Milan, Italy Cosmo Pharmaceuticals S.p.A. (SIX:COPN), Lainate, Italy Business: Neurology WIR Staff Neurology...
BioCentury | Feb 22, 2010
Company News

BioXell, Lay Line, Roche deal

BioXell terminated its 2006 deal with Lay Line Genomics for exclusive rights to Lay Line's BXL1H5 (formerly MNAC13 ) technology. BioXell will return all rights to Lay Line for the humanized antibody against TrkA ( NTRK1 ;...
BioCentury | Feb 15, 2010
Company News

BioXell, Cosmo deal

Cosmo completed its initial tender offer for BioXell, acquiring about 5.1 million shares (94.8%) at €5, or about €25.5 million ($34.9 million). The additional acceptance period for the offer begins on Feb. 15 and ends...
BioCentury | Jan 4, 2010
Company News

BioXell, Novo Nordisk deal

BioXell sold Novo Nordisk its triggering receptors expressed on myeloid cells (TREM) 1 program for €1 million ($1.4 million). The deal includes compounds targeting TREM1 and research tools. BioXell is being acquired by Cosmo Pharmaceuticals...
BioCentury | Dec 7, 2009
Company News

BioXell management update

BioXell S.p.A. (SIX:BXLN), Milan, Italy Business: Genitourinary, Musculoskeletal, Neurology Departed: Laurence Skillern as CMO WIR Staff Genitourinary Musculoskeletal Neurology...
BioCentury | Nov 23, 2009
Finance

Ebb & Flow

Movetis N.V. is looking to what could be the biggest European biotech IPO in the last two years, and if all the stars align, more than any new offering in Europe in more than five...
BioCentury | Nov 23, 2009
Company News

BioXell, Cosmo deal

Specialty pharmaceutical company Cosmo will acquire BioXell in a cash, stock and put option transaction that the companies said values BioXell at CHF7.68 per share, or CHF41.3 million ($41 million) based on 5.4 million shares...
BioCentury | Nov 19, 2009
Company News

Cosmo to acquire BioXell

Specialty pharmaceutical company Cosmo Pharmaceuticals S.p.A. (SIX:COPN) will acquire BioXell S.p.A. (SIX:BXLN) in a cash, stock and put option transaction that the companies said values BioXell at CHF7.68 per share, or CHF41.3 million ($41 million),...
Items per page:
1 - 10 of 121
BioCentury | May 12, 2014
Emerging Company Profile

Inotrem: Sepsis companion

Inotrem S.A. is betting that a companion diagnostic can help its TREM1 inhibitors tamp down inflammation in the right sepsis patients and improve its odds of success in an indication where the only approved drug...
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BioCentury | Mar 15, 2010
Company News

BioXell, Cosmo deal

Cosmo completed its previously announced acquisition of BioXell (see BioCentury, Nov. 23, 2009). BioXell S.p.A. (SIX:BXLN), Milan, Italy Cosmo Pharmaceuticals S.p.A. (SIX:COPN), Lainate, Italy Business: Neurology WIR Staff Neurology...
BioCentury | Feb 22, 2010
Company News

BioXell, Lay Line, Roche deal

BioXell terminated its 2006 deal with Lay Line Genomics for exclusive rights to Lay Line's BXL1H5 (formerly MNAC13 ) technology. BioXell will return all rights to Lay Line for the humanized antibody against TrkA ( NTRK1 ;...
BioCentury | Feb 15, 2010
Company News

BioXell, Cosmo deal

Cosmo completed its initial tender offer for BioXell, acquiring about 5.1 million shares (94.8%) at €5, or about €25.5 million ($34.9 million). The additional acceptance period for the offer begins on Feb. 15 and ends...
BioCentury | Jan 4, 2010
Company News

BioXell, Novo Nordisk deal

BioXell sold Novo Nordisk its triggering receptors expressed on myeloid cells (TREM) 1 program for €1 million ($1.4 million). The deal includes compounds targeting TREM1 and research tools. BioXell is being acquired by Cosmo Pharmaceuticals...
BioCentury | Dec 7, 2009
Company News

BioXell management update

BioXell S.p.A. (SIX:BXLN), Milan, Italy Business: Genitourinary, Musculoskeletal, Neurology Departed: Laurence Skillern as CMO WIR Staff Genitourinary Musculoskeletal Neurology...
BioCentury | Nov 23, 2009
Finance

Ebb & Flow

Movetis N.V. is looking to what could be the biggest European biotech IPO in the last two years, and if all the stars align, more than any new offering in Europe in more than five...
BioCentury | Nov 23, 2009
Company News

BioXell, Cosmo deal

Specialty pharmaceutical company Cosmo will acquire BioXell in a cash, stock and put option transaction that the companies said values BioXell at CHF7.68 per share, or CHF41.3 million ($41 million) based on 5.4 million shares...
BioCentury | Nov 19, 2009
Company News

Cosmo to acquire BioXell

Specialty pharmaceutical company Cosmo Pharmaceuticals S.p.A. (SIX:COPN) will acquire BioXell S.p.A. (SIX:BXLN) in a cash, stock and put option transaction that the companies said values BioXell at CHF7.68 per share, or CHF41.3 million ($41 million),...
Items per page:
1 - 10 of 121